Phospho-TBK1 (Ser172) Antibody (YA7414)
(Synonyms: NAK, TBK1, Serine/threonine-protein kinase TBK1, NF-kappa-B-activating kinase, T2K, TANK-binding kinase 1)
Based on 1 Customer Validation
Phospho-TBK1 (Ser172) Antibody (YA7414) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Phospho-TBK1 (Ser172).
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, ICC/IF, ELISA
-
Reactivity :
Human, Mouse, Rat
-
Formulation:
Supplied in PBS (pH7.4) containing 50% glycerol, 0.05% Proclin 300, 0.05%BSA
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|---|
| Dilution Ratio | 1:2000-1:10000 | 1:200-1:1000 | 1:5000-1:20000 |
Product Details
Phospho-TBK1 (Ser172) Antibody (YA7414) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Phospho-TBK1 (Ser172).
-
Host Rabbit
-
Clonality Monoclonal,Recombinant
-
Species ReactivityHuman, Mouse, Rat
-
Observed Molecular WeightObserved band size: 84 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 84 kDa
The exact sequence is proprietary to MCE.
Endogenous
Protein A affinity purified
Non-conjugated
Phosphorylated
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS (pH7.4) containing 50% glycerol, 0.05% Proclin 300, 0.05%BSA
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
TANK-binding kinase 1 (TBK1) is a serine/threonine kinase central to innate immune signaling, mediating phosphorylation of IRF3/7 to induce type I interferon (IFN) and interferon-stimulated genes (ISGs) [1][2]. Mechanistically, TBK1 participates in antiviral defense via the RIG-I-like receptor (RLR) and TLR pathways, promoting IRF3 nuclear translocation and IFN-β production[3][4][5]. Alternative splicing generates TBK1 isoforms that can negatively regulate antiviral responses by disrupting TBK1-IRF3 interactions, facilitating proteasomal degradation of TBK1 and lysosomal degradation of IRF3[3][4][6][5]. TBK1 also supports AKT/mTORC1 pathway activation in cancer, influencing cellular proliferation and survival, with context-dependent effects in KRAS-mutant lung cancers[7][2]. Dysregulated TBK1 activity is associated with autoimmune diseases, interferonopathies, and cancer, highlighting its therapeutic relevance[1][8][9]. Pharmacological inhibition using small molecules such as BX795 and amlexanox modulates TBK1-mediated signaling, suppressing inflammation, cellular senescence, and IFN production in disease models, while agonists of downstream effectors like IRF3 can enhance antiviral responses[10][11][8]. Compared with related kinases, TBK1 demonstrates isoform-specific regulation of IFN signaling and unique interactions with viral or cellular substrates, distinguishing its function from IKKε and other IKK family members[12][13]. High-throughput assays and computational QSAR models have facilitated the discovery of selective TBK1 inhibitors, providing tools for experimental modulation of innate immune and oncogenic pathways[12][14]. Collectively, TBK1 acts as a central hub in innate immunity, cancer biology, and inflammatory regulation, with isoform-specific roles and pharmacological manipulability informing research design[2][15].
-
Subcellular Localization
Cytoplasm
-
Expression
Tissue_Specificity: Ubiquitous with higher expression in testis. Expressed in the ganglion cells, nerve fiber layer and microvasculature of the retina -
Isoforms & Post-Translational Modification
Q9UHD2: 729 amino acids, molecular weight 83642 Da.
-
Subunit
Homodimer (PubMed:21145761, PubMed:37926288)
-
SwissProt ID
-
Synonyms
NAK, TBK1, Serine/threonine-protein kinase TBK1, NF-kappa-B-activating kinase, T2K, TANK-binding kinase 1
Documentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
User Guide for Antibodies (1077 KB)
References
[1]. Zhang J, et al. A Novel Transcript Isoform of TBK1 Negatively Regulates Type I IFN Production by Promoting Proteasomal Degradation of TBK1 and Lysosomal Degradation of IRF3. Front Immunol. 2020 Sep 30;11:580864. [Content Brief]
[2]. Hu YW, et al. TANK-Binding Kinase 1 (TBK1) Isoforms Negatively Regulate Type I Interferon Induction by Inhibiting TBK1-IRF3 Interaction and IRF3 Phosphorylation. Front Immunol. 2018 Jan 30;9:84. [Content Brief]
[3]. Zhang J, et al. TBK1 Isoform Inhibits Grass Carp Reovirus Infection by Targeting the Degradation of Viral Nonstructural Proteins NS80 and NS38. J Immunol. 2023 Jan 15;210(2):191-203. [Content Brief]
[4]. Hasan M, et al. Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies. Pharmacol Res. 2016 Sep;111:336-342. [Content Brief]
[5]. Ji W, et al. TBK1 and IRF3 are potential therapeutic targets in Enterovirus A71-associated diseases. PLoS Negl Trop Dis. 2023 Jan 10;17(1):e0011001. [Content Brief]
[6]. Zhang M, et al. Inhibitory targeting cGAS-STING-TBK1 axis: Emerging strategies for autoimmune diseases therapy. Front Immunol. 2022 Sep 12;13:954129. [Content Brief]
[7]. Cooper JM, et al. TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer. Cancer Res. 2017 Sep 15;77(18):5077-5094. [Content Brief]
[8]. Hutti JE, et al. Development of a high-throughput assay for identifying inhibitors of TBK1 and IKKε. PLoS One. 2012;7(7):e41494. [Content Brief]
[9]. Yeo SK, et al. AZI2 mediates TBK1 activation at unresolved selective autophagy cargo receptor complexes with implications for CD8 T-cell infiltration in breast cancer. Autophagy. 2024 Mar;20(3):525-540. [Content Brief]
[10]. Deng W, et al. Negative regulation of virus-triggered IFN-beta signaling pathway by alternative splicing of TBK1. J Biol Chem. 2008 Dec 19;283(51):35590-7. [Content Brief]
[11]. Runde AP, et al. The role of TBK1 in cancer pathogenesis and anticancer immunity. J Exp Clin Cancer Res. 2022 Apr 9;41(1):135. [Content Brief]
[12]. Ivanov JM, et al. In Silico Insights: QSAR Modeling of TBK1 Kinase Inhibitors for Enhanced Drug Discovery. J Chem Inf Model. 2024 Oct 14;64(19):7488-7502. [Content Brief]
[13]. Lu R, et al. TBK1 pharmacological inhibition mitigates osteoarthritis through attenuating inflammation and cellular senescence in chondrocytes. J Orthop Translat. 2024 Jun 28;47:207-222. [Content Brief]
[14]. Hui L, et al. Amlexanox targeted inhibition of TBK1 regulates immune cell function to exacerbate DSS-induced inflammatory bowel disease. Clin Exp Immunol. 2025 Jan 21;219(1):uxae082. [Content Brief]
[15]. Ding C, et al. Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway. Acta Pharm Sin B. 2020 Dec;10(12):2272-2298. [Content Brief]
Powered by Bioz
